Ipsen announces it is no longer eligible for the PEA-PME scheme
Ipsen (Euronext: IPN; ADR: IPSEY) announces that the Group is no longer eligible for the PEA-PME scheme (a French equity savings vehicle for small and mid-sized business enterprises) as of January 1st, 2018, in accordance with Articles L221-32-2 and D221-113-5 of the French Monetary and Financial Code.
As of January 1st, 2018, the Group will no longer comply with the thresholds set by the legislator for eligibility to the PEA-PME scheme, determined on the basis of two fiscal years preceding the acquisition date of the securities i.e. the consolidated financial statements for 2016, in accordance with the French regulations.
Consequently, Ipsen Group’s securities can no longer be included in PEA-PME accounts but are still eligible for the traditional PEA scheme.
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
Ipsen announces changes to its Executive Committee
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary...